RT Journal Article
SR Electronic
T1 A national mixed-mode seroprevalence random population-based cohort on SARS-CoV-2 epidemic in France: the socio-epidemiological EpiCov study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.24.21252316
DO 10.1101/2021.02.24.21252316
A1 Warszawski, Josiane
A1 Bajos, Nathalie
A1 Barlet, Muriel
A1 de Lamballerie, Xavier
A1 Rahib, Delphine
A1 Lydié, Nathalie
A1 Durrleman, S
A1 Slama, Rémy
A1 Seng, Rémonie
A1 Raynaud, Philippe
A1 Leduc, Aude
A1 Bagein, Guillaume
A1 Paliod, Nicolas
A1 Legleye, Stéphane
A1 Favre-Martinoz, Cyril
A1 Castell, Laura
A1 Sillard, Patrick
A1 Meyer, Laurence
A1 Beck, François
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/02/26/2021.02.24.21252316.abstract
AB Background the EpiCov study, initiated at the end of the first national lockdown in France, aimed to provide national and regional estimates of the seroprevalence of SARS-CoV-2 infection, and to analyze relations between living conditions and the dynamics of the epidemic. We present and discuss here the survey methodology, and describe the first-round fieldwork.Method 371,000 individuals aged 15 years or more were randomly selected from the national tax register, stratified by departments, including three overseas departments, and by poverty level with over-representation of people living below the poverty line. Health, socio-economics, migration history, and living conditions were collected through self-computed-assisted web interviews or via computer-assisted telephone interviews. The first-round survey was conducted in May. A random subsample was eligible to receive material for home blood self-sample on dried blood spot (DBS), in order to detect IgG antibodies against the spike protein (Euroimmun ELISA-S), and neutralizing antibodies for non-negative ELISA-S. For the second-round conducted in November, all respondents were eligible for the antibodies detection from home DBS sample, as well as the other household members aged 6 years or more for 20% of them.Participation and adjustment for nonresponse 134,391 respondents completed the first-round questionnaire from May 2 to June 1, 2020, including 16,970 (12.6%) respondents under the poverty line. Multimodal web/tel interviews was randomly assigned to 20% of the sample. The other were assigned to exclusive CAWI. Overall 17,441 respondents were eligible for home blood sample, among them 12,114 returned the DBS (interquartile date: May 25-June 5). The response probability was first estimated from logit models adjusted on a wide range of auxiliary demographic and socio-economic variables available from the sampling frame, and final weights calibrated to the margins of the population census permitted to correct for a large part of the non-response bias.Conclusion The Epicov study is one of the largest national random population-based seroprevalence cohort, with both an epidemiological and sociological approaches to evaluate the spread of the COVID-19 epidemic, and the impact on health and living conditions. One of the major interests of this study is the broad coverage of the socio-economic and territorial diversity of the population.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04378582Funding StatementThis research was supported by research grants from Inserm (Institut National de la Santé et de la Recherche Médicale) and the French Ministry for Research, by Drees-Direction de la Recherche, des Etudes, de Evaluation et des Statistiques, and the French Ministry for Health; by the Région Ile de FranceAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the appropriate committees. The EpiCov cohort protocol was approved by the CPP (Comite de Protection des Personnes, French equivalent of the Research Ethics Committee) on April 24, 2020, and amended on June 5. A notice of opportunity from the National Council for Statistical Information (CNIS) was obtained on April 17, 2020, and approval was obtained from the Comite du label de la statistique publique on April 21, 2020, proving its adequacy to statistical quality standards, and from the CNIL (Commission nationale de informatique et des libertes, the French independent administrative authority responsible for data protection) on April 25, 2020. All these committees modified their procedures to ensure rapid processing and a fast implementation of the study. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and analyzed during the current study are available from the corresponding author on reasonable request.